Recurrent glioblastoma: Nuances and insights

CC BY-NC-ND 4.0 · Asian J Neurosurg 2021; 16(01): 228-229
DOI: 10.4103/ajns.AJNS_395_20

Commentary

Maysam Alimohamadi

Department of Neurosurgery, Sina Hospital, Tehran University of Medical Sciences, Tehran

,

Amirhossein Larijani

Department of Neurosurgery, Sina Hospital, Tehran University of Medical Sciences, Tehran

References
1 Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, et al. Lomustine and Bevacizumab in Progressive Glioblastoma. N Engl J Med 2017;377:1954-63.
2 Bloch O, Han SJ, Cha S, Sun MZ, Aghi MK, McDermott MW, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: Clinical article. J Neurosurg 2012;117:1032-8.
3 Archavlis E, Tselis N, Birn G, Ulrich P, Zamboglou N. Combined salvage therapies for recurrent glioblastoma multiforme: Evaluation of an interdisciplinary treatment algorithm. J Neurooncol 2014;119:387-95.
4 Franceschi E, Bartolotti M, Tosoni A, Bartolini S, Sturiale C, Fioravanti A. The effect of re-operation on survival in patients with recurrent glioblastoma. Anticancer Res. 2015 Mar;35(3):1743-8.
5 Chaul-Barbosa C, Marques DF. How We Treat Recurrent Glioblastoma Today and Current Evidence. Curr Oncol Rep 2019;21:94.
6 Day BW, Stringer BW, Al-Ejeh F, Ting MJ, Wilson J, Ensbey KS, et al. EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme. Cancer Cell 2013;23:238-48.
7 An Z, Aksoy O, Zheng T, Fan QW, Weiss WA. Epidermal growth factor receptor and EGFRvIII in glioblastoma: Signaling pathways and targeted therapies. Oncogene 2018;37:1561-75.
8 Osuka S, Van Meir EG. Overcoming therapeutic resistance in glioblastoma: The way forward. J Clin Invest 2017;127:415-26.